Neil Martinson

Researcher Next ID · RN-043183

Researcher · Immunology and Microbiology

Johns Hopkins University

Baltimore, South Africa

Accepting doctoral researchersFunding unknown

Works count: 455
Citation count: 12,362
H-index: 54
i10-index: 214

Research interests

Immunology and Microbiology

Medicine

Tuberculosis Research and Epidemiology

HIV/AIDS Research and Interventions

Pneumocystis jirovecii pneumonia detection and treatment

HIV Research and Treatment

HIV/AIDS drug development and treatment

Publications

SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020–21
The Lancet Infectious Diseases · 2022 · https://doi.org/10.1016/s1473-3099(22)00069-x
The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions
The Lancet Respiratory Medicine · 2022 · https://doi.org/10.1016/s2213-2600(22)00092-3
SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020–21
The Lancet Infectious Diseases · 2022 · https://doi.org/10.1016/s1473-3099(22)00069-x
Asymptomatic transmission and high community burden of seasonal influenza in an urban and a rural community in South Africa, 2017–18 (PHIRST): a population cohort study
The Lancet Global Health · 2021 · https://doi.org/10.1016/s2214-109x(21)00141-8
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis
New England Journal of Medicine · 2021 · https://doi.org/10.1056/nejmoa2033400
Asymptomatic transmission and high community burden of seasonal influenza in an urban and a rural community in South Africa, 2017–18 (PHIRST): a population cohort study
The Lancet Global Health · 2021 · https://doi.org/10.1016/s2214-109x(21)00141-8
The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis
The Lancet · 2020 · https://doi.org/10.1016/s0140-6736(20)30166-5
Final Analysis of a Trial of M72/AS01 E Vaccine to Prevent Tuberculosis
New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1909953
Phase 2b Controlled Trial of M72/AS01 E Vaccine to Prevent Tuberculosis
New England Journal of Medicine · 2018 · https://doi.org/10.1056/nejmoa1803484
Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection
Annals of Internal Medicine · 2017 · https://doi.org/10.7326/m17-1150
Controlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infection
The Lancet · 2015 · https://doi.org/10.1016/s0140-6736(15)00323-2
New Regimens to Prevent Tuberculosis in Adults with HIV Infection
New England Journal of Medicine · 2011 · https://doi.org/10.1056/nejmoa1005136
Body mass index and risk of tuberculosis and death
AIDS · 2010 · https://doi.org/10.1097/qad.0b013e32833a2a4a
Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort
AIDS · 2009 · https://doi.org/10.1097/qad.0b013e328327964f
Tuberculosis in Africa — Combating an HIV-Driven Crisis
New England Journal of Medicine · 2008 · https://doi.org/10.1056/nejmp0800809
Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission
Proceedings of the National Academy of Sciences · 2006 · https://doi.org/10.1073/pnas.0602033103
Emergence of Drug‐Resistant HIV‐1 after Intrapartum Administration of Single‐Dose Nevirapine Is Substantially Underestimated
The Journal of Infectious Diseases · 2005 · https://doi.org/10.1086/430741

Current projects

No projects listed.